Core Viewpoint - Tianjin Development (00882.HK) announced that Lifesun Pharmaceutical (002393.SZ) achieved a revenue of 1.007 billion yuan in the first three quarters of 2025, reflecting a year-on-year decrease of 1.61% while net profit attributable to shareholders increased by 119.05% to 370 million yuan [1] Financial Performance - Lifesun Pharmaceutical's revenue for the first three quarters of 2025 was 1.007 billion yuan, down 1.61% year-on-year [1] - The net profit attributable to shareholders reached 370 million yuan, showing a significant increase of 119.05% compared to the previous year [1] - The net profit excluding non-recurring gains and losses was 127 million yuan, which represents a year-on-year growth of 19.21% [1] - Basic earnings per share were reported at 1.44 yuan [1]